Skip to main content
    T

    Trinity Biotech plc (TRIB)

    Official site

    HEALTHCARE • MEDICAL DEVICES • NASDAQ

    $6.01
    +0.64 (+11.81%)

    Market Cap: $4.96M

    Last updated: Nov 17, 2026 at 4:15 PM ET

    Trinity Biotech plc (TRIB) Statistics

    Updated Nov 17, 2026. Figures from company filings and market prices; estimates from consensus analysts.

    Trinity Biotech (TRIB) has a market cap of $4.96M and an enterprise value of $137.81M. Its net debt of $132.84M equals 2678.27% of its market cap. It kept -97.33% of revenue as net income over the last 12 months.

    Total Valuation

    Enterprise value is 2678.27% above the market cap, as debt exceeds cash.

    Market Cap$4.96M
    Enterprise Value$137.81M
    Latest price (Nov 17, 2026)$6.01

    Key Dates

    The next earnings report is expected on Dec 22, 2026, covering the quarter ending Sep 30, 2026.

    Next Earnings DateDec 22, 2026 (expected)
    Last Earnings DateApr 30, 2026
    Fiscal Year EndDecember

    Share Statistics

    The share count fell 99.83% in the quarter ended Mar 31, 2026 and grew 44.89% a year over 2 years.

    Shares Outstanding620.90K
    Shares Change (YoY)+1.80%
    Shares Change (QoQ)-99.83%
    Share Count Growth (2Y CAGR)+44.89%

    Price Statistics

    The stock is down 77.21% over 52 weeks and trades 11.49% below its 50-day average.

    Beta (1Y)1.74
    52-Week Change-77.21%
    1-Month Change-26.62%
    3-Month Change-45.41%
    6-Month Change-64.55%
    5-Year Change-97.98%
    10-Year Change-99.39%
    Total Return (1Y)-77.21%
    Total Return (3Y CAGR)-52.85%
    Total Return (5Y CAGR)-53.95%
    Return vs SPY (1Y)-87.23%
    Max Drawdown (1Y)-86.09%
    Max Drawdown (3Y)-94.85%
    Sharpe Ratio (1Y)-1.23
    Correlation with SPY (1Y)0.21
    50-Day Average$6.79
    200-Day Average$14.31
    52-Week Range$5.00 to $52.50
    RSI (14 Days)45.0
    Average Volume (20 Days)11.30K

    The 5 and 10 year changes compare month-end closes, adjusted for splits, through Oct 2026.

    Price chart

    Financial Position

    Current assets cover 0.25x current liabilities.

    Current Ratio0.25x
    Quick Ratio0.12x
    Interest Coverage-0.30x

    Returns and Efficiency

    Return on invested capital is -14.34% over the last 12 months, against a 5-year average of -31.12%.

    Return on Assets (ROA)-35.54%
    Return on Invested Capital (ROIC)-14.34%
    ROA (5Y Average)-30.10%
    ROIC (5Y Average)-31.12%
    Asset Turnover0.46x
    Inventory Turnover1.58x
    Receivables Turnover4.82x
    Cash Conversion Cycle54 days

    Scores

    TRIB has an Altman Z-Score of -2.58, in the distress zone below 1.81, and a Piotroski F-Score of 3 of 9, in the average band of 3 to 7.

    Altman Z-Score-2.58
    Altman Z ZoneDistress
    Piotroski F-Score3 of 9
    Piotroski StrengthAverage

    Income Statement

    Revenue of $47.35M over the last 12 months is down 13.00% from the 12 months before.

    Revenue$47.35M
    Revenue Growth (YoY)-13.00%
    Gross Profit$17.51M
    Operating Income-$9.47M
    Pretax Income-$46.06M
    Net Income-$46.08M
    EBITDA-$6.69M
    EBIT-$9.47M
    Reported EPS (TTM)-$1,316.05

    Trailing 12 months through Mar 31, 2026.

    Full financial statements

    Balance Sheet

    Cash and Equivalents$5.14M
    Total Debt$137.98M
    Net Debt$132.84M
    Working Capital-$105.31M
    Shareholder Equity-$71.98M
    Tangible Book Value-$128.97M
    Total Assets$105.17M
    Total Liabilities$177.15M

    Balance sheet as of Mar 31, 2026.

    Full balance sheet

    Cash Flow

    After $65.64K of capital spending, operating cash flow left -$4.91M of free cash flow.

    Operating Cash Flow-$4.85M
    Capital Expenditures$65.64K
    Free Cash Flow-$4.91M
    FCF Per Share-$5.95
    Depreciation and Amortization$2.78M

    Trailing 12 months through Mar 31, 2026.

    Full cash flow statement

    Margins

    The operating margin is -19.99%, against a 5-year average of -25.52%.

    Gross Margin36.98%
    Operating Margin-19.99%
    Pretax Margin-97.28%
    Net Margin-97.33%
    EBITDA Margin-14.12%
    EBIT Margin-19.99%
    FCF Margin-10.37%
    Gross Margin (5Y Average)36.82%
    Operating Margin (5Y Average)-25.52%
    Net Margin (5Y Average)-48.75%

    Growth

    Revenue fell 11.20% a year over 3 years.

    Revenue Growth (3Y CAGR)-11.20%
    Revenue Growth (5Y CAGR)-15.56%

    Revenue and profit by year

    Dividends and Yields

    TRIB does not pay a dividend.

    Buyback Yield-0.06%
    Shareholder Yield-0.06%

    Stock Splits

    The last split was a 1-for-30 reverse split on Jul 24, 2026.

    Last Split DateJul 24, 2026
    Split TypeReverse split
    Split Ratio1:30

    Peer Position

    Against 7 similar companies, TRIB has the 2nd highest ROIC.

    ROIC-14.34% vs -147.05% median
    Revenue Growth (Trailing 4 Quarters, YoY)-13.00% vs +46.22% median

    Competitors compared

    Analyst Forecast

    Consensus estimates put revenue growth at 35.89% a year over the next fiscal year.

    Revenue Growth Forecast (1Y CAGR)+35.89%

    Price Target

    Analyst price targets are part of paid GNG plans. See plans

    Frequently Asked Questions About TRIB

    What is TRIB's market cap?

    Trinity Biotech has a market cap of $4.96M. Its enterprise value, which adds debt and subtracts cash, is $137.81M.

    How many shares of TRIB are outstanding?

    Trinity Biotech has 620.90K shares outstanding. The count is up 1.80% from a year earlier.

    Does TRIB pay a dividend?

    No. Trinity Biotech does not pay a dividend.

    How much debt does TRIB have?

    Trinity Biotech has $137.98M of total debt and $5.14M of cash and equivalents, a net debt position of $132.84M.